{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:49:05Z","timestamp":1791802145220,"version":"4.3.4"},"reference-count":20,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the future, treatment of dementia will be personalized, targeted to contributing pathologies, rather than the clinical syndrome. Anti\u2010amyloid drugs for Alzheimer's disease are the first approved drugs; however, the impact of co\u2011pathology on the treatment effects remains incomplete. Currently, only patients with a clinical diagnosis of Alzheimer's disease are eligible for these new drugs, but could they also be beneficial when amyloid is present in other neurodegenerative diseases? For example, roughly 50% of patients with dementia with Lewy bodies are amyloid\u2010positive. In this perspective, we discuss the theoretical benefits and challenges of anti\u2010amyloid drugs in patients with a clinical diagnosis of dementia with Lewy bodies and concomitant Alzheimer's disease pathology. We show that a significant portion of newly diagnosed dementia with Lewy bodies patients could be eligible. We advocate for the systematic collection of efficacy and safety data using innovative strategies to achieve adequate statistical power.<\/jats:p>","DOI":"10.1002\/alz.71907","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:25:59Z","timestamp":1791800759000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dementia with Lewy bodies and amyloid pathology: Eligible for anti\u2010amyloid treatment or not?"],"prefix":"10.1002","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1475-536X","authenticated-orcid":false,"given":"Lieza G","family":"Exalto","sequence":"first","affiliation":[{"name":"Alzheimer Center Department of Neurology Amsterdam Neuroscience Amsterdam UMC Vrije Universiteit Amsterdam  Amsterdam The Netherlands"},{"name":"Julius Clinical  Zeist The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette L","family":"van Alphen","sequence":"additional","affiliation":[{"name":"Alzheimer Center Department of Neurology Amsterdam Neuroscience Amsterdam UMC Vrije Universiteit Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine Amsterdam UMC Vrije Universiteit Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory Department of Laboratory Medicine Amsterdam Neuroscience Amsterdam UMC Vrije Universiteit Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everard G. B","family":"Vijverberg","sequence":"additional","affiliation":[{"name":"Alzheimer Center Department of Neurology Amsterdam Neuroscience Amsterdam UMC Vrije Universiteit Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[{"name":"Centre for Age\u2010Related Medicine Stavanger University Hospital  Stavanger Norway"},{"name":"Department of Psychological Medicine Institute of Psychiatry Psychology and Neuroscience King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afina W","family":"Lemstra","sequence":"additional","affiliation":[{"name":"Alzheimer Center Department of Neurology Amsterdam Neuroscience Amsterdam UMC Vrije Universiteit Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"Van Dyck CH","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER\u2010ALZ 2 randomized clinical trial","volume":"330","author":"Sims JR","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"e_1_2_9_4_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici GD","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings J","year":"2023","journal-title":"J Prev Alzheimers Dis."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102025\u2010336597"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14467"},{"issue":"98","key":"e_1_2_9_8_1","first-page":"e1262","article-title":"Association of the ATN research framework with clinical profile, cognitive decline, and mortality in patients with Dementia with lewy bodies","volume":"22","author":"Beek M","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium","volume":"89","author":"Mckeith IG","year":"2017","journal-title":"Neurology"},{"issue":"10004","key":"e_1_2_9_10_1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(15)00462-6","article-title":"Lewy body dementias","volume":"386","author":"Walker Z","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40120-023-00467-8","article-title":"Dementia with lewy bodies drug therapies in clinical trials: systematic teview up to 2022","volume":"12","author":"Abdelnour C","year":"2023","journal-title":"Neurol Ther"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107255"},{"issue":"24","key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"E3257","DOI":"10.1212\/WNL.0000000000010943","article-title":"\u03b2\u2010Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies","volume":"95","author":"Ferreira D","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072\u2010025\u201008725\u20103"},{"issue":"3","key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3233\/JAD-170850","article-title":"Amsterdam dementia cohort: performing research to optimize care","volume":"62","author":"Van Der Flier WM","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010022\u201001124\u20102"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010024\u201001502\u2010y"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209605"},{"issue":"9","key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jalz.2019.02.002","article-title":"Effects of single and combined immunotherapy approach targeting amyloid \u03b2 protein and \u03b1\u2010synuclein in a dementia with Lewy bodies\u2013like model","volume":"15","author":"Mandler M","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"9247","key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","article-title":"Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double\u2010blind, placebo\u2010controlled international study","volume":"356","author":"McKeith I","year":"2000","journal-title":"Lancet"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010022\u201001015\u20106"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71907","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.71907","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:26:01Z","timestamp":1791800761000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.71907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/alz.71907"],"URL":"https:\/\/doi.org\/10.1002\/alz.71907","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71907"}}